• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开启开源建模工具的辩论:火上浇油还是扑灭健康辩论的火花。

Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate.

机构信息

Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.

Certara UK Limited (Simcyp Division), Sheffield, UK.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):420-427. doi: 10.1002/psp4.12615. Epub 2021 May 1.

DOI:10.1002/psp4.12615
PMID:33793084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8129708/
Abstract

As model-informed drug development becomes an integral part of modern approaches to the discovery of new therapeutic entities and showing their safety and effectiveness, modalities of incorporating the paradigm into widespread practice require a revisit. Traditionally, modeling and simulation (M&S) have been performed by specialized teams who create bespoke models for each case and have reservations about letting modeling be done by the greater mass of scientists engaged in various stages of drug development. An analogy can be drawn between M&S and automobiles: typical drivers of ordinary cars use them for daily tasks, such as going from point A to B whereas specialized Formula 1 drivers using bespoke individually made cars to test the latest technologies. The reliability and robustness of ordinary cars for the first group requires elements related to quality and endurance that are very different from those applicable to any Formula 1 car supported by a large team of engineers. In this commentary, we frame and analyze the problems concerning the structure and setup of various M&S tools, and their pros and cons. We demonstrate that many misconceptions have precluded having an open discussion on what each modality of M&S tools strives to achieve, and we provide data and evidence that support the move of M&S to main stream use by many, as opposed to specialized usage by few. Parallels are drawn in many other areas involving laboratory instrumentation, statistical analyses, and so on.

摘要

随着模型引导药物研发成为新药发现和展示其安全性和有效性的现代方法的一个组成部分,将该范例纳入广泛实践的方式需要重新审视。传统上,建模和模拟 (M&S) 是由专门的团队进行的,他们为每个案例创建定制模型,并对让更多从事药物研发各个阶段的科学家进行建模持保留态度。可以将 M&S 与汽车进行类比:普通汽车的典型驾驶员将其用于日常任务,例如从 A 点到 B 点,而专门的一级方程式驾驶员则使用定制的个人汽车来测试最新技术。对于第一组,普通汽车的可靠性和耐用性需要与适用于由大量工程师支持的任何一级方程式赛车相关的质量和耐久性元素非常不同。在这篇评论中,我们构建并分析了各种 M&S 工具的结构和设置及其优缺点所涉及的问题。我们表明,许多误解使得对 M&S 工具的每种模式努力实现的目标进行公开讨论变得不可能,并提供数据和证据支持将 M&S 推向许多人的主流使用,而不是少数人的专门使用。在涉及实验室仪器、统计分析等的许多其他领域也进行了类比。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b2b/8129708/8220348f94d5/PSP4-10-420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b2b/8129708/8220348f94d5/PSP4-10-420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b2b/8129708/8220348f94d5/PSP4-10-420-g001.jpg

相似文献

1
Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate.开启开源建模工具的辩论:火上浇油还是扑灭健康辩论的火花。
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):420-427. doi: 10.1002/psp4.12615. Epub 2021 May 1.
2
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).大分子拥挤现象:化学与物理邂逅生物学(瑞士阿斯科纳,2012年6月10日至14日)
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 2.
3
Injuries to car occupants--some aspects of the interior safety of cars. A study of a five-year material from an insurance company.汽车驾乘人员受伤情况——汽车内部安全的若干方面。对一家保险公司五年资料的研究。
Acta Otolaryngol Suppl. 1984;395:1-164. doi: 10.3109/00016488309139642.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Evolution of ADME science: where else can modeling and simulation contribute?ADME 科学的演进:建模和模拟还能在哪些方面做出贡献?
Mol Pharm. 2013 Apr 1;10(4):1162-70. doi: 10.1021/mp3005319. Epub 2013 Jan 22.
6
Vehicle registration year, age, and weight - Untangling the effects on crash risk.车辆注册年份、年龄和重量——厘清对碰撞风险的影响。
Accid Anal Prev. 2019 Feb;123:1-11. doi: 10.1016/j.aap.2018.11.002. Epub 2018 Nov 15.
7
Variations of significant contribution regions of NO and PN emissions for passenger cars in the real-world driving.实际行驶工况下轿车 NO 和 PN 排放的显著贡献区域变化。
J Hazard Mater. 2022 Feb 15;424(Pt C):127590. doi: 10.1016/j.jhazmat.2021.127590. Epub 2021 Oct 27.
8
Car mass and fatality risk: has the relationship changed?汽车质量与死亡风险:这种关系有变化吗?
Am J Public Health. 1994 Jan;84(1):33-6. doi: 10.2105/ajph.84.1.33.
9
Involvement rate in two-car crashes versus driver age and car mass of each involved car.两车相撞事故的发生率与驾驶员年龄及每辆涉案车辆的车重的关系
Accid Anal Prev. 1985 Apr;17(2):155-70. doi: 10.1016/0001-4575(85)90018-1.
10

引用本文的文献

1
Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator.将Simcyp R包与Simcyp模拟器一起用于PBPK模拟工作流程。
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):853-863. doi: 10.1002/psp4.70022. Epub 2025 Apr 3.
2
Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.实现 Project Optimus 的承诺:肿瘤药物开发中剂量优化的挑战和新兴机遇。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):691-709. doi: 10.1002/psp4.13079. Epub 2024 Mar 21.
3
Current practices for QSP model assessment: an IQ consortium survey.

本文引用的文献

1
Reproducibility in systems biology modelling.系统生物学建模中的可重复性。
Mol Syst Biol. 2021 Feb;17(2):e9982. doi: 10.15252/msb.20209982.
2
Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.过去 20 年来,基于生理学的药代动力学模型在药物研发中的发展趋势;对应用、组织和平台的深入分析。
Biopharm Drug Dispos. 2021 Apr;42(4):107-117. doi: 10.1002/bdd.2257. Epub 2021 Jan 17.
3
Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences.
当前定量构效关系模型评价实践:IQ 联盟调查。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):543-555. doi: 10.1007/s10928-022-09811-1. Epub 2022 Aug 11.
4
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib.基于生理学的 SARS-CoV-2 感染患者药代动力学建模方法:以伊马替尼为例的病例研究。
J Clin Pharmacol. 2022 Oct;62(10):1285-1296. doi: 10.1002/jcph.2065. Epub 2022 May 8.
5
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.用于 Simcyp 基于人群的模拟器中 PBPK 建模的复合文件开发指南。
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):805-821. doi: 10.1002/psp4.12791. Epub 2022 Apr 18.
6
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations.儿科生理基于药代动力学模型在学术和行业组织中的应用不断增加。
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):373-383. doi: 10.1002/psp4.12764. Epub 2022 Feb 17.
7
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.体外到体内外推与基于生理的药代动力学模型相关联,用于评估脑内药物处置。
AAPS J. 2022 Jan 13;24(1):28. doi: 10.1208/s12248-021-00675-w.
8
Physiologically based pharmacokinetic modelling in pregnancy: Model reproducibility and external validation.妊娠的基于生理的药代动力学模型:模型再现性和外部验证。
Br J Clin Pharmacol. 2022 Feb;88(4):1441-1451. doi: 10.1111/bcp.15018. Epub 2021 Aug 26.
9
A latent variable approach to account for correlated inputs in global sensitivity analysis.一种在全局敏感性分析中考虑相关输入的潜在变量方法。
J Pharmacokinet Pharmacodyn. 2021 Oct;48(5):671-686. doi: 10.1007/s10928-021-09764-x. Epub 2021 May 25.
开放系统药理学社区——一种用于药学科学建模与模拟的开放获取、开源、开放科学方法。
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):878-882. doi: 10.1002/psp4.12473. Epub 2019 Nov 12.
4
Come Dance With Me: Transformative Changes in the Science and Practice of Drug-Drug Interactions.来与我共舞:药物相互作用的科学与实践的变革。
Clin Pharmacol Ther. 2019 Jun;105(6):1272-1278. doi: 10.1002/cpt.1433. Epub 2019 Apr 20.
5
Clinical Pharmacokinetic Studies in Pregnant Women and the Relevance of Pharmacometric Tools.临床孕妇药代动力学研究及药代动力学工具的相关性。
Curr Pharm Des. 2019;25(5):483-495. doi: 10.2174/1381612825666190320135137.
6
A Comprehensive Framework for Physiologically-Based Pharmacokinetic Modeling in Matlab.Matlab中基于生理学的药代动力学建模综合框架
CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):444-459. doi: 10.1002/psp4.12399. Epub 2019 Apr 2.
7
Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities.定量系统药理学模型的可重复性:当前的挑战和未来的机遇。
CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):205-210. doi: 10.1002/psp4.12390. Epub 2019 Mar 3.
8
Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.模型引导药物研发:当前美国监管实践与未来考量
Clin Pharmacol Ther. 2019 Apr;105(4):899-911. doi: 10.1002/cpt.1363. Epub 2019 Mar 1.
9
Model Informed Drug Development and Regulation in China: Challenges and Opportunities.中国的模型引导药物研发与监管:挑战与机遇
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):59-61. doi: 10.1002/psp4.12368. Epub 2019 Jan 4.
10
Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models.妊娠的生理药代动力学模型:已发表模型的系统评价。
Clin Pharmacol Ther. 2018 Dec;104(6):1110-1124. doi: 10.1002/cpt.1084. Epub 2018 May 6.